Roche Pharmaceutical Development and Sales Overview slide image

Roche Pharmaceutical Development and Sales Overview

Tecentriq (atezolizumab, RG7446) Anti-PD-L1 cancer immunotherapy - urothelial carcinoma Indication 1L metastatic urothelial carcinoma (UC) High-risk non-muscle-invasive bladder cancer (MIBC) ctDNA+, high-risk muscle-invasive bladder cancer (MIBC) Phase/study # of patients Design ■ Primary endpoint " " Status ☐ CT Identifier " Phase III IMvigor 130 N=1,200 ARM A: Tecentriq plus gemcitabine and carboplatin or cisplatin ARM B: Tecentriq monotherapy ARM C: Placebo plus gemcitabine and carboplatin or cisplatin Progression-free survival, overall survival and safety FPI Q3 2016 FPI for arm B (amended study) Q1 2017 Recruitment completed Q3 2018 Study met co-primary endpoint of PFS Q3 2019 Data presented at ESMO 2019 and AACR 2021 Data published in Lancet 2020 May 16;395(10236):1547-1557 NCT02807636 Phase III ALBAN N=516 ARM A: BCG induction and maintenance ARM B: Tecentriq plus BCG induction and maintenance " Recurrence-free survival FPI Q4 2018 NCT03799835 Phase III IMvigor011 N=495 ARM A: Tecentriq monotherapy " ARM B: Placebo Recurrence-free survival ◉ FPI Q2 2021 NCT04660344 BCG-Bacille Calmette-Guérin; PD-L1-Programmed cell death-ligand 1; PFS-Progression-free survival; AACR-American Association for Cancer Research; ESMO-European Society for Medical Oncology Roche 70 10 Oncology
View entire presentation